ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference

Core Insights - ProKidney Corp. is a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD) [1][2] - The company will participate in two upcoming healthcare conferences in November 2025, including the Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference [1] Company Overview - ProKidney was founded in 2015 after a decade of research and is a pioneer in the treatment of CKD through innovations in cellular therapy [2] - The lead product candidate, rilparencel (REACT), is a first-in-class, patented, proprietary autologous cellular therapy with regenerative medicine advanced therapy designation [2] - Rilparencel is currently being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes [2]